Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 9, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	12	59	71	60	121	159
Market Cap Growth	-88.67%	-16.43%	17.53%	-50.38%	-23.75%	-
Enterprise Value	3	46	66	46	105	159
Last Close Price	0.28	1.44	2.73	2.35	5.20	6.82

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 9, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
PB Ratio	1.41	5.08	18.57	5.68	8.06	7.44
P/TBV Ratio	1.41	5.08	18.57	5.68	8.06	7.44

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 9, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Debt / Equity Ratio	-1.14	-1.00	-0.81	-1.06	-0.97	-0.93
Quick Ratio	6.12	23.99	11.87	10.52	28.39	82.71
Current Ratio	6.24	24.53	13.46	10.92	30.40	89.61
Return on Equity (ROE)	-69.69%	-109.69%	-113.80%	-91.42%	-37.42%	-249.85%
Return on Assets (ROA)	-45.04%	-71.09%	-65.97%	-54.05%	-22.93%	-18.30%
Return on Capital Employed (ROCE)	-114.70%	-79.10%	-217.90%	-111.20%	-45.30%	-16.90%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 9, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Earnings Yield	-67.06%	-14.34%	-11.58%	-19.48%	-5.62%	-19.00%
Buyback Yield / Dilution	-55.97%	-30.97%	-2.98%	-7.41%	-71.49%	-13.44%

Data Source: S&P Global Market Intelligence Last updated: Feb 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error